NA
IOVA icon

NewEdge Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

NewEdge Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.9K Hold
5,035
– – ﹤0.01% 3347
2026
Q1 		$17.7K Buy
5,035
+100
+2% +$320 ﹤0.01% 3233
2025
Q4 		$13.5K Hold
4,935
– – ﹤0.01% 3378
2025
Q3 		$10.7K Buy
4,935
+310
+7% +$732 ﹤0.01% 3308
2025
Q2 		$7.96K Buy
4,625
+500
+12% +$1.24K ﹤0.01% 3275
2025
Q1 		$13.7K Buy
4,125
+490
+13% +$2.53K ﹤0.01% 2987
2024
Q4 		$26.9K Hold
3,635
– – ﹤0.01% 2720
2024
Q3 		$34.1K Hold
3,635
– – ﹤0.01% 2552
2024
Q2 		$29.2K Buy
3,635
+500
+16% +$5.36K ﹤0.01% 2513
2024
Q1 		$46.5K Buy
3,135
+1,335
+74% +$15.5K ﹤0.01% 2339
2023
Q4 		$14.6K Hold
1,800
– – ﹤0.01% 2702
2023
Q3 		$8.19K Buy
1,800
+1,100
+157% +$7.18K ﹤0.01% 2645
2023
Q2 		$4.93K Buy
+700
New +$5.01K ﹤0.01% 2823

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

NewEdge Advisors's IOVA Position: Q2 2026 in Review

NewEdge Advisors held its Iovance Biotherapeutics (IOVA) position steady in Q2 2026 at 5,035 shares worth $20.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3347.

NewEdge Advisors first reported a position in IOVA in Q2 2023 and has held it in 13 quarters since. The position peaked at $46.5K in Q1 2024. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • NewEdge Advisors held 5,035 shares of Iovance Biotherapeutics worth $20.9K as of Q2 2026.
  • NewEdge Advisors left its Iovance Biotherapeutics share count unchanged in Q2 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3347 holding.
  • NewEdge Advisors first reported a position in Iovance Biotherapeutics in Q2 2023 and has held it in 13 quarters since.
  • NewEdge Advisors's Iovance Biotherapeutics position peaked at $46.5K in Q1 2024.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.